MARKET

VKTX

VKTX

Viking Therapeutics Inc
NASDAQ
21.97
+0.01
+0.05%
Pre Market: 22.10 +0.13 +0.59% 07:38 06/02 EDT
OPEN
21.90
PREV CLOSE
21.96
HIGH
22.33
LOW
21.55
VOLUME
10
TURNOVER
--
52 WEEK HIGH
25.72
52 WEEK LOW
2.020
MARKET CAP
2.19B
P/E (TTM)
-23.4272
1D
5D
1M
3M
1Y
5Y
XBI, IMGN, TGTX, VKTX: Large Inflows Detected at ETF
NASDAQ · 1d ago
Why Viking Therapeutics Stock Is Heating Up Today
Motley Fool · 1d ago
Viking Therapeutics a buy at Roth on NASH candidate and pipeline
Seeking Alpha · 2d ago
Roth MKM Assumes Viking Therapeutics at Buy, Announces Price Target of $32
Benzinga · 2d ago
2 Growth Stocks That Doubled in 2023 and Could Shoot 55% to 87% Higher, According to Wall Street
Motley Fool · 3d ago
Drug pricing watchdog raises alarm over upcoming liver disease meds
Seeking Alpha · 3d ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
NASDAQ · 4d ago
My Methods For Finding The Best Stock Portfolio, Part 3
Seeking Alpha · 05/26 15:10
More
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRb). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. The Company’s other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).

Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.